Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Guardian examines cervical cancer in Africa

The Guardian examines how Africa is handling cervical cancer, which is the second most common cancer among women on the continent.

21 Jun 2011

HPV vaccine shows success in young Australian women, study says

"A vaccine to prevent cervical cancer, triggered by the human papillomavirus (HPV), has helped reduce the number of teenage girls developing abnormalities in their cervix by as much as 50 percent in a study in Australia," according to a report published Friday in the Lancet, Reuters reports.

18 Jun 2011

Cancer vaccine shows promise

In the latest research news, a cervical cancer vaccine programme has produced the first evidence of disease prevention among treated women. This vaccine targets human papillomavirus (HPV), the virus believed to trigger cervical cancer in women.

17 Jun 2011

Cancer professionals urge world leaders to attend U.N. meeting on NCDs

The American Society of Clinical Oncology (ASCO) on Monday sent a letter signed by major U.S. medical societies representing about 300,000 health care professionals to the White House urging President Barack Obama to participate in the U.N. High Level Meeting on Noncommunicable Diseases that is scheduled for September, Agence France-Presse reports.

9 Jun 2011

Several drug makers plan to lower prices of vaccines for GAVI purchase

Several pharmaceutical companies have pledged to lower the prices of vaccines against childhood illnesses ahead of the GAVI Alliance conference in London next week, the Guardian reports (Quinn, 6/6).

6 Jun 2011

New blog aims to help dispel many myths behind cervical smear test

In the UK, 20 per cent of women still do not attend smear tests, putting themselves at risk of leaving pre-cancerous cervical cells undetected. A new blog, entitled, 'my diary from down under', aims to help dispel many of the myths surrounding having a smear with the aim of putting women at ease and encouraging more women to attend their cervical screens when invited.

6 Jun 2011

GAVI welcomes lower pentavalent vaccine price

In the lead up to its first pledging conference on June 13, the GAVI Alliance announced today it has achieved commitments from two emerging market vaccine manufacturers to lower prices for the life-saving pentavalent vaccine, which protects against five deadly diseases. Developed country manufacturers have also offered price reductions on rotavirus and human papillomavirus, or HPV, vaccines.

5 Jun 2011

Study offers hope for reducing incidence of AIDS with potential preventive vaccine

The HIV epidemic is the largest in the world and represents one of the most serious public health problems, according to data from the World Health Organization. Only 30% of the more than 10 million patients in need have the access to the antiretroviral treatment.

24 May 2011

Australians discover treatment for very common female infection

Starpharma Holdings Limited has announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV).

22 May 2011

Coordinated efforts required to close gaps in preventive behavior: American Cancer Society

A new report from the American Cancer Society details cancer control efforts and outlines improvements as well as gaps in preventive behavior that contribute to cancer mortality.

21 May 2011

Groundbreaking cancer treatment studies to be unveiled at AAPS National Biotechnology Conference

Cancer studies from Mercer University headline groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC).

13 May 2011

New GARDASIL data against Human Papillomavirus presented at EUROGIN conference

A real-world study evaluating the safety of GARDASIL among 189,629 females in California found no serious adverse events related to vaccination, no safety signals for any health event resulting in an emergency room visit or hospitalization and no safety signals associated with pre-specified autoimmune conditions or pregnancy outcomes.

9 May 2011

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.

9 May 2011

Rwanda launches Africa's first nationwide cervical cancer vaccination, detection program

Rwandan First Lady Jeannette Kagame on Tuesday, in collaboration with two companies, launched a national cervical cancer vaccination and screening program, the first of its kind in Africa, the New Times reports.

27 Apr 2011

Researchers develop protein-based inhibitor that can treat HPV

Human papillomavirus causes cervical cancer, the second most common cause of cancer death for women, and is a common cause of anogenital and some head and neck cancers.

27 Apr 2011

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.

26 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Roche's cobas HPV Test receives FDA approval for cervical cancer screening

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This test will help physicians make early, more accurate decisions about patient care, which may prevent many women from developing this deadly disease.

From Roche Sequencing and Life Science 20 Apr 2011

Cervical cancer vaccine target falls short: Report

Data from the Australian federal government shows that the target to immunize 80 per cent of 12-year-old girls against cervical cancer is not being met because many of them are failing to have all three doses of the vaccine. This potentially undermines the effectiveness of the $436 million program started in 2007.

19 Apr 2011

Safer-sex education leads to fewer episodes of unprotected sex

Teaching young women how to prevent sexually transmitted infections (STIs) increases condom use and might reduce their number of sexual partners, but little research exists on whether educational programs reduce rates of STIs such as human papillomavirus, according to an updated research review from England.

15 Apr 2011

Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Guardian examines cervical cancer in Africa

HPV vaccine shows success in young Australian women, study says

Cancer vaccine shows promise

Cancer professionals urge world leaders to attend U.N. meeting on NCDs

Several drug makers plan to lower prices of vaccines for GAVI purchase

New blog aims to help dispel many myths behind cervical smear test

GAVI welcomes lower pentavalent vaccine price

Study offers hope for reducing incidence of AIDS with potential preventive vaccine

Australians discover treatment for very common female infection

Coordinated efforts required to close gaps in preventive behavior: American Cancer Society

Groundbreaking cancer treatment studies to be unveiled at AAPS National Biotechnology Conference

New GARDASIL data against Human Papillomavirus presented at EUROGIN conference

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Rwanda launches Africa's first nationwide cervical cancer vaccination, detection program

Researchers develop protein-based inhibitor that can treat HPV

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

Roche's cobas HPV Test receives FDA approval for cervical cancer screening

Cervical cancer vaccine target falls short: Report

Safer-sex education leads to fewer episodes of unprotected sex

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in